isotretinoin has been researched along with Meningeal-Neoplasms* in 2 studies
1 review(s) available for isotretinoin and Meningeal-Neoplasms
| Article | Year |
|---|---|
Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin.
Cancer has been reported in patients with systemic lupus erythematosus (SLE). A possible association of the development of hematologic malignancies in patients with SLE has been suggested. In some patients, subacute cutaneous lupus erythematosus, a distinct subset of lupus erythematosus, has appeared, resolved, or both as a solid tumor-related paraneoplastic syndrome. A woman in whom a meningioma was diagnosed 44 years following the onset of subacute cutaneous lupus erythematosus is described; her skin lesions improved after starting isotretinoin therapy. The relationship between lupus erythematosus and neoplasia is summarized and the management of subacute cutaneous lupus erythematosus with retinoids is reviewed. Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Clobetasol; Dermatologic Agents; Female; Fluocinonide; Glucocorticoids; Humans; Isotretinoin; Lupus Erythematosus, Cutaneous; Meningeal Neoplasms; Meningioma | 2000 |
1 other study(ies) available for isotretinoin and Meningeal-Neoplasms
| Article | Year |
|---|---|
Improving medical approaches to primary CNS malignancies--retinoid therapy and more.
Successfully inducing differentiation in ectodermal diseases, retinoids harbour considerable therapeutic potential in the treatment of neuroectodermal-neuroepithelial malignancies. The principal tissue retinoid, retinoic acid, can be potently upregulated in vivo by a relatively specific catabolic inhibitor, R75251 (liarozole). Both substances have been given orally over 2 years in addition to standard treatment, and have been well tolerated. Corresponding closely to plasma retinoid levels, cutaneous side effects facilitate individual dosing. We evaluate this adjuvant retinoid approach and additional efforts to improve therapy of primary CNS malignancies, including the topical administration of retinoids in gamma linolenic acid. Topics: Aged; Aged, 80 and over; Brain Neoplasms; Cell Differentiation; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Imidazoles; Isotretinoin; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Retinoids; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Vitamin A | 1993 |